We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Regulators find Danish drugmaker sponsored ‘disguised’ promotional campaign
Healthcare professionals encouraged to prescribe group’s weight loss drug as part of ‘disguised’ promotional campaign
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy
Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?
Academic institutions must balance private and public interests
HSBC embarks on a cost-cutting drive that threatens up to 10,000 jobs
Danish pharma group has faced criticism in the US over its pricing
Dual-class structures carry risks but can also give patient investors a stronger voice
Cost increase for essential medicine comes as drugmakers face political pressure
Better marketing might be the answer to thin sales
Danish pharma group seeks to exploit potential of AI and big data
Deal could eventually be worth more than $800m if milestones are met
Pricing pressures prompt cautious outlook at Danish pharma group
EU companies may feel brunt of US sanctions after Trump pulls out of nuclear deal
Danish drugmaker beats expectations with 6% increase in operating earnings
Repair Impact Fund will help start-ups develop treatment aimed at drug-resistant bacteria
Novo Nordisk misses revenue expectations while Roche cautions on stagnant sales
If the Danish group wants to bulk up its sickly biopharma unit, it will need to be less cautious
Biotech blockbuster acquisition is second in a week and latest in sector M&A boom
French group beats interest from Novo Nordisk to make second major acquisition in a week
Shares in target company jump after it rejects unsolicited bid as undervalued
Investors should sit tight for what promises to be an elaborate courtship
International Edition
